Ianalumab (VAY736), a novel BAFF inhibitor targeting BAFF receptor, has attracted great attention as a promising therapeutic agent for SLE and Sjögren syndrome (119). The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.